In this issue of The Journal of the American Medical Directors Association (JAMDA), Voelker and colleagues present the results of a systematic review and meta-analysis
measuring the reliability and concurrent validity of the SARC-F.
1
The study reports data gathered from 29 articles and more than 20,000 participants.
Overall, the SARC-F shows relatively good inter-rater and test-retest reliability.
However, the authors conclude that despite its high specificity, the low to moderate
sensitivity of the SARC-F makes it nonoptimal for the screening of sarcopenia. Moreover,
Voelker and colleagues tend to discourage the use of the SARC-F, suggesting the direct
application of the diagnostic criteria for sarcopenia without prior screening.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Reliability and concurrent validity of the SARC-F and its modified versions: A systematic review and meta-analysis.J Am Med Dir Assoc. 2021; 22: 1864-1876
- SARC-F for screening of sarcopenia among older adults: A meta-analysis of screening test accuracy.J Am Med Dir Assoc. 2018; 19: 685-689
- Sarcopenia is recognized as an independent condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) code.J Am Med Dir Assoc. 2016; 17: 675-677
- Implications of ICD-10 for sarcopenia clinical practice and clinical trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force.J Frailty Aging. 2018; 7: 2-9
- Sarcopenia the new geriatric giant: Time to translate research findings into clinical practice.Age Ageing. 2014; 43: 736-737
- Sarcopenia: An emerging giant greater than osteoporosis.Ann Geriatr Med Res. 2016; 20: 167
- Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.J Cachexia Sarcopenia Muscle. 2012; 3: 181-190
- Sarcopenia definition: The position statements of the Sarcopenia Definition and Outcomes Consortium.J Am Geriatr Soc. 2020; 68: 1410-1418
- Sarcopenia: Revised European consensus on definition and diagnosis.Age Ageing. 2019; 48: 16-31
- Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment.J Am Med Dir Assoc. 2020; 21: 300-307.e2
- Sarcopenia in daily practice: Assessment and management.BMC Geriatr. 2016; 16: 170
- Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults.Aging Clin Exp Res. 2021; 33: 3-17
- Investigating sarcopenia awareness using Google Trends.J Frailty Sarcopenia Falls. 2021; 6: 32-35
- Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives.J Nutr Health Aging. 2008; 12: 433-450
- SARC-F: A simple questionnaire to rapidly diagnose sarcopenia.J Am Med Dir Assoc. 2013; 14: 531-532
- Rapid geriatric assessment: A tool for primary care physicians.J Am Med Dir Assoc. 2017; 18: 195-199
- A 3-item SARC-F.J Am Med Dir Assoc. 2018; 19: 223-228
- SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes.J Cachexia Sarcopenia Muscle. 2016; 7: 28-36
Article info
Footnotes
M.C. reported receiving personal fees from Nestlé. Emanuele Marzetti reported receiving personal fees from Abbott, Nestlè, Nutricia, and Thermo Fisher. R.C. reported receiving personal fees from Abbott and Nutricia.
Identification
Copyright
© 2021 Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.
